Lycera Announces Key Appointments to Board of Directors

ANN ARBOR, Mich.--(BUSINESS WIRE)--Lycera Corp., a biopharmaceutical company pioneering innovative approaches to developing novel oral medicines to treat autoimmune diseases, today announced that Steven Gillis, Ph.D., managing director of ARCH Venture Partners, has been appointed chairman of the board of directors, replacing Jeffrey Leiden, M.D., Ph.D., of Clarus Ventures, who has stepped down from the board. The company also announced that Michael Steinmetz, Ph.D., managing director of Clarus Ventures, has joined the board of directors.